The second objective is to delineate theranostic biomarkers, which may be used in the clinical practice as predictors of PC above and beyond the effects of prostate-specific antigen (PSA), even as potential therapy aimed at its inhibition. The gene discussed is KLK3; the disease is pachyonychia congenita.